cd38 e7z8c cell signaling technologies Search Results


cd38  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc cd38
Validation of B-cell presence in FFPE tumor tissue of patients with PPBC PW , Pr-BC, and NP-BC and correlation with prognosis by means of multiplex IF (mIF) CD20 + labeling, TAPC scoring, and singleplex IHC <t>CD38</t> labeling. A, Representative image of the two designed mIF panels showing staining for CD3, CD20, CD27, FoxP3, CD8, and CD138 markers. B, Cell density was estimated for all patient groups and visualized as a log10 transformation with a pseudocount of 1. Significance was calculated using Wilcoxon rank-sum test (pairwise) or a Kruskal–Wallis test (between all groups). CD20 + CD3 − CD8 − cells—further described as CD20 + cells—(representing nonplasma B cells). No significant difference in CD20 + densities (number of cells/total tissue area) were observed between patients with PP-BC PW ( n = 44) and NP-BC ( n = 58; Wilcoxon, P = 0.10). mIF patient groups below the minimum power threshold of n = 15 (Pr-BC, n = 11 and PP-BC DL , n = 7) are visualized but not subjected to statistical tests (see decision tree visualized in Supplementary Fig. S1). C, Kaplan–Meier OS curve for all patient groups with adequate sample size and follow-up >20 months. Pr-BC and PP-BC DL were excluded from mIF survival curves due to low sample numbers delivering insufficient power (see decision tree visualized in Supplementary Fig. S1). Neither high nor low CD20 + mIF density was not significantly associated with OS between PP-BC PW and NP-BC, as determined via a log-rank test. D, CD20 + /CD20 + clustering (normalized cellular colocalization within a fixed radius of 0.30 mm) indicate a significantly decreased clustering in patients with PP-BC PW compared with NP-BC (Wilcoxon, P = 0.03), whereas ( E ) no difference in survival can be observed based on CD20 + /CD20 + clustering. F, Representative image of a patient with PP-BC PW with high and low TAPC counts in the tumor area as evaluated in an H&E-stained FFPE slide. G, Patients with PP-BC PW ( n = 66) present with significantly higher TAPC counts compared with patients with Pr-BC ( n = 51) and NP-BC ( n = 76; Wilcoxon, P = 0.011). H, Although no significant difference in survival rates was seen between patient groups with low TAPC scores (score “0”–“1”), patients with PP-BC PW with high TAPC scores (score “2”–“3”) were associated with a significantly increased risk for death (log-rank P = 0.03) compared with patients with Pr-BC and NP-BC. Only PP-BC DL ( n = 17) was excluded. I, Representative image of CD38 + IHC staining showing high and low densities of CD38 + plasma cells of a patient with PP-BC PW . J, Significantly increased intratumoral CD38 + plasma cell density in the tumor area of patients with PP-BC PW ( n = 50) versus patients with NP-BC ( n = 63; Wilcoxon, P < 0.01). K, Although no significant difference in survival rates was seen between patient groups with low intratumoral CD38 + densities, patients with PP-BC PW with high intratumoral CD38 + densities had a significantly increased risk for death (log-rank P = 0.02) compared with patients with NP-BC. Significant P values are indicated with an asterix (*).
Cd38, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+e7z8c+cell+signaling+technologies/CD38+XP+Rabbit+mAb/pmc10502474-94-16-22
Average 94 stars, based on 1 article reviews
cd38 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
cd38 xp rabbit mab  (Cell Signaling Technology Inc)
N/A
Cyclic ADP-ribose hydrolase 1 (CD38) is a transmembrane protein involved in several important biological processes, including immune response, insulin secretion, and social behavior. Originally described as a glycosylated immune cell surface marker, additional research determined
   Buy from Supplier

Image Search Results


Validation of B-cell presence in FFPE tumor tissue of patients with PPBC PW , Pr-BC, and NP-BC and correlation with prognosis by means of multiplex IF (mIF) CD20 + labeling, TAPC scoring, and singleplex IHC CD38 labeling. A, Representative image of the two designed mIF panels showing staining for CD3, CD20, CD27, FoxP3, CD8, and CD138 markers. B, Cell density was estimated for all patient groups and visualized as a log10 transformation with a pseudocount of 1. Significance was calculated using Wilcoxon rank-sum test (pairwise) or a Kruskal–Wallis test (between all groups). CD20 + CD3 − CD8 − cells—further described as CD20 + cells—(representing nonplasma B cells). No significant difference in CD20 + densities (number of cells/total tissue area) were observed between patients with PP-BC PW ( n = 44) and NP-BC ( n = 58; Wilcoxon, P = 0.10). mIF patient groups below the minimum power threshold of n = 15 (Pr-BC, n = 11 and PP-BC DL , n = 7) are visualized but not subjected to statistical tests (see decision tree visualized in Supplementary Fig. S1). C, Kaplan–Meier OS curve for all patient groups with adequate sample size and follow-up >20 months. Pr-BC and PP-BC DL were excluded from mIF survival curves due to low sample numbers delivering insufficient power (see decision tree visualized in Supplementary Fig. S1). Neither high nor low CD20 + mIF density was not significantly associated with OS between PP-BC PW and NP-BC, as determined via a log-rank test. D, CD20 + /CD20 + clustering (normalized cellular colocalization within a fixed radius of 0.30 mm) indicate a significantly decreased clustering in patients with PP-BC PW compared with NP-BC (Wilcoxon, P = 0.03), whereas ( E ) no difference in survival can be observed based on CD20 + /CD20 + clustering. F, Representative image of a patient with PP-BC PW with high and low TAPC counts in the tumor area as evaluated in an H&E-stained FFPE slide. G, Patients with PP-BC PW ( n = 66) present with significantly higher TAPC counts compared with patients with Pr-BC ( n = 51) and NP-BC ( n = 76; Wilcoxon, P = 0.011). H, Although no significant difference in survival rates was seen between patient groups with low TAPC scores (score “0”–“1”), patients with PP-BC PW with high TAPC scores (score “2”–“3”) were associated with a significantly increased risk for death (log-rank P = 0.03) compared with patients with Pr-BC and NP-BC. Only PP-BC DL ( n = 17) was excluded. I, Representative image of CD38 + IHC staining showing high and low densities of CD38 + plasma cells of a patient with PP-BC PW . J, Significantly increased intratumoral CD38 + plasma cell density in the tumor area of patients with PP-BC PW ( n = 50) versus patients with NP-BC ( n = 63; Wilcoxon, P < 0.01). K, Although no significant difference in survival rates was seen between patient groups with low intratumoral CD38 + densities, patients with PP-BC PW with high intratumoral CD38 + densities had a significantly increased risk for death (log-rank P = 0.02) compared with patients with NP-BC. Significant P values are indicated with an asterix (*).

Journal: Clinical Cancer Research

Article Title: Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features

doi: 10.1158/1078-0432.CCR-22-3645

Figure Lengend Snippet: Validation of B-cell presence in FFPE tumor tissue of patients with PPBC PW , Pr-BC, and NP-BC and correlation with prognosis by means of multiplex IF (mIF) CD20 + labeling, TAPC scoring, and singleplex IHC CD38 labeling. A, Representative image of the two designed mIF panels showing staining for CD3, CD20, CD27, FoxP3, CD8, and CD138 markers. B, Cell density was estimated for all patient groups and visualized as a log10 transformation with a pseudocount of 1. Significance was calculated using Wilcoxon rank-sum test (pairwise) or a Kruskal–Wallis test (between all groups). CD20 + CD3 − CD8 − cells—further described as CD20 + cells—(representing nonplasma B cells). No significant difference in CD20 + densities (number of cells/total tissue area) were observed between patients with PP-BC PW ( n = 44) and NP-BC ( n = 58; Wilcoxon, P = 0.10). mIF patient groups below the minimum power threshold of n = 15 (Pr-BC, n = 11 and PP-BC DL , n = 7) are visualized but not subjected to statistical tests (see decision tree visualized in Supplementary Fig. S1). C, Kaplan–Meier OS curve for all patient groups with adequate sample size and follow-up >20 months. Pr-BC and PP-BC DL were excluded from mIF survival curves due to low sample numbers delivering insufficient power (see decision tree visualized in Supplementary Fig. S1). Neither high nor low CD20 + mIF density was not significantly associated with OS between PP-BC PW and NP-BC, as determined via a log-rank test. D, CD20 + /CD20 + clustering (normalized cellular colocalization within a fixed radius of 0.30 mm) indicate a significantly decreased clustering in patients with PP-BC PW compared with NP-BC (Wilcoxon, P = 0.03), whereas ( E ) no difference in survival can be observed based on CD20 + /CD20 + clustering. F, Representative image of a patient with PP-BC PW with high and low TAPC counts in the tumor area as evaluated in an H&E-stained FFPE slide. G, Patients with PP-BC PW ( n = 66) present with significantly higher TAPC counts compared with patients with Pr-BC ( n = 51) and NP-BC ( n = 76; Wilcoxon, P = 0.011). H, Although no significant difference in survival rates was seen between patient groups with low TAPC scores (score “0”–“1”), patients with PP-BC PW with high TAPC scores (score “2”–“3”) were associated with a significantly increased risk for death (log-rank P = 0.03) compared with patients with Pr-BC and NP-BC. Only PP-BC DL ( n = 17) was excluded. I, Representative image of CD38 + IHC staining showing high and low densities of CD38 + plasma cells of a patient with PP-BC PW . J, Significantly increased intratumoral CD38 + plasma cell density in the tumor area of patients with PP-BC PW ( n = 50) versus patients with NP-BC ( n = 63; Wilcoxon, P < 0.01). K, Although no significant difference in survival rates was seen between patient groups with low intratumoral CD38 + densities, patients with PP-BC PW with high intratumoral CD38 + densities had a significantly increased risk for death (log-rank P = 0.02) compared with patients with NP-BC. Significant P values are indicated with an asterix (*).

Article Snippet: In a subsequent single-plex IHC experiment, whole tissue slides were incubated with an antibody specific for CD38 (clone E7Z8C, Catalog No. 51000S, Cell Signaling Technology, 1/40,000 dilution, 1 hour at RT), as a potential marker for plasma cells.

Techniques: Biomarker Discovery, Multiplex Assay, Labeling, Staining, Transformation Assay, Immunohistochemistry, Clinical Proteomics